• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·China·Healthcare·300896.SZ
Share

Imeik Technology Development Co.,Ltd. Stocks

CN¥ 89.07Last Updated 10.09.2026

Issuer Rating

5/7
Performance

Favourable

Risk

Limited

Recommendation

Hold

Market Cap

CN¥ 4.22B

CN¥ 89.07
Key Takeaways

Risk factor

Strong trading liquidity

Data is available to registered users only
Data is available to registered users only

Profitability factor

Very strong margins and returns

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

Imeik Technology Development Co.,Ltd. specializes in the research, development, manufacturing, and distribution of biomedical materials. The company's diverse product portfolio caters to both the medical aesthetics field and general skincare needs. Within its medical beauty offerings, Imeik provides a range of recognized brands including Moisten Angel, IFRESH, Yimei, Hearty, Bonita Bonita, and Tightly. Additionally, its comprehensive skincare line features hydrating lotions, anti-aging and firming serums, concentrated essence creams, revitalizing facial masks, restorative chitosan B5 sprays, and clarifying and illuminating liquids. Established in 2004, the company's operations are based in Beijing, China.

Company Valuation

Slightly overvalued
3/7

From both historical and forecast perspectives, the stock is slightly overpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalued o

Data is available to registered users only
Sign up to access detailed valuation

Target Price

Favourable
6/7

The average target price of 300896.SZ is 132 and suggests 45.1% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to

Data is available to registered users only
Sign up to access analyst forecasts

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

11.09.2026 17:37

Inflation in the U.S. in August came in slightly above expectations. What can we expect from the Fed now?

11.09.2026 17:24

"A Recipe for Volatility": Why BofA Sees Risks in Market Calm

11.09.2026 15:00

Uber's CEO Invested $10 Million in the Company's Shares, Which Had Fallen in Price

11.09.2026 13:30

An investor from "Shorting" advised buying wine amid the dollar's decline

11.09.2026 13:11

Diesel prices in the U.S. have exceeded $6 per gallon for the first time in history

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026